Jannie Borst - Selected Publications#

Borst, J., Ahrends, T., Bąbała, N., Melief, C.J. & Kastenmüller, W. CD4+ T-cell help in cancer immunology and immunotherapy.
Nat. Rev. Immunol. 18: 635-647, 2018. PMID: 30057419. IF 46.5

- Review outlining the importance of CD4+ T cells in orchestrating the cytotoxic T cell response to cancer and infectious disease (based on Ahrends et al. 2017)

Cuadrado, E., van den Biggelaar, M*., de Kivit, S*., Chen, Y.-Y., Slot, M., Doubal, I., Meijer, A., van Lier, R.A.W., Borst, J.* & Amsen D.A*. Quantitative proteomics reveals a unique wiring of signaling pathways that defines human regulatory T cell identity. *equal contribution.
Immunity 48: 1046-1059, 2018. PMID: 29752063. IF 19.7

- Discovery of the alternative "wiring" of key signal transduction pathways in suppressive regulatory CD4+ T cells as opposed to conventional CD4+ T cells. Provides openings for new drug development to deliberately steer T cell responses in disease.

Ahrends, T., Spanjaard, A., Pilzecker, B., Bąbała, N., Bovens, A., Xiao, Y., Jacobs, H. & Borst, J. CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness.
Immunity 47: 848-861, 2017. PMID: 29126798. IF 19.7

- Identification of the molecular program instilled into cytotoxic T cells as a result of help provided by CD4+ T cells.
- Of key importance for development of strategies in cancer immunotherapy

Ahrends, T., Bąbała, N., Xiao, Y., Yagita, H., van Eenennaam, H. & Borst, J. CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination.
Cancer Res. 76: 2921-2931, 2016. PMID: 27020860. IF 9.1

- Key paper that provided the incentive for pharma to start clinical development of the agnostic antibody to CD27 that Jannie Borst developed together with dr. Hans van Eenennaam (the inventor of Pembrolizumab)

Hendriks, J., Gravestein, L.A., Tesselaar, K., van Lier, R.A.W., Schumacher, T.N.M. & Borst, J. CD27 is required for generation and long-term maintenance of T cell immunity.
Nat. Immunol. 1: 433-440, 2000. PMID: 11062504. Citations 628; IF 25

- First documentation of the in vivo importance of the CD27 costimulatory receptor that Jannie Borst and colleagues identified in the human system in 1987

Peters, P.J., Geuze, H.J., van der Donk, H.A., Slot, J.W., Griffith, J.M., Stam, N.J., Clevers, H.C. & Borst, J. Molecules relevant for T-cell target cell interaction are present in cytolytic granules of human T lymphocytes.
Eur. J. Immunol. 19: 1469-1475, 1989. PMID: 2789142. Citations 201; IF 4.5

- First visualization of the immune synapse and exocytic profiles of cytotoxic granules in high resolution (by EM) and start of the exosome field

Borst, J., van Dongen, J.J.M., Bolhuis, R.L.H., Peters, P., Hafler, D.A., de Vries, E. & van de Griend, R.J. Distinct molecular forms of human TCR gamma delta detected on viable T cells by a monoclonal antibody.
J. Exp. Med. 167: 1625-1644, 1988. PMID: 2966845. IF 12.5

- Generation and diagnostic use of an antibody that allowed the first identification of gamma delta T cells in human blood and tissues

Borst, J., van de Griend, R.J., van Oostveen, J.W., Ang, S.-L., Melief, C.J., Seidman, J.G. & Bolhuis, R.L.H. A T cell receptor  gamma CD3 complex found on cloned functional lymphocytes.
Nature (article) 325: 683-688, 1987. PMID: 3102966. IF 38.1

- Discovery of the human gamma delta T cell lineage

Borst, J., Alexander, S., Elder, J. & Terhorst, C. The T3 complex on human T lymphocytes involves four structurally distinct glycoproteins. J. Biol. Chem. 258: 5135-5141,1983. PMID: 6220014. IF 5.5

- Discovery of the CD3 complex, responsible for signal transduction by the T cell antigen receptor

For citations see https://scholar.google.nl/citations?user=GAbksc4AAAAJ&hl=nl